^
Association details:
Biomarker:NRAS G12D
Cancer:Acute Lymphocytic Leukemia
Drug:U0126 (MEK1 inhibitor, MEK2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia

Excerpt:
...NRAS G12D mutation but is WT for other components of the pathway, was similarly treated and examined for pERK inhibition. There was complete inhibition of pERK by 10 μmol/L U0126 ( Fig. 5A ) and 20 μmol/L PD98059 (data not shown) after both 8 and 24 h of incubation and a cytotoxic effect was seen for both compounds.
DOI:
10.1158/0008-5472.CAN-08-0101